Please login to the form below

Not currently logged in
Email:
Password:

ankylosing spondylitis

This page shows the latest ankylosing spondylitis news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos close in on filing for Xeljanz rival

Gilead and Galapagos close in on filing for Xeljanz rival

RA and the rest from other diseases such as psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

Latest news

  • Novartis gains label boost for Cosentyx Novartis gains label boost for Cosentyx

    Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis.

  • Gilead and Galapagos JAK contender scores in RA trial Gilead and Galapagos JAK contender scores in RA trial

    The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis. ... The new results for filgotinib follow close behind

  • Gilead, Galapagos JAK inhibitor clears phase II test Gilead, Galapagos JAK inhibitor clears phase II test

    A mid-stage trial of Gilead and Galapagos’ JAK1 inhibitor filgotinib has set up a phase III programme for the drug in ankylosing spondylitis as it chases down two already-marketed

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    Sandoz’ Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

More from news
Approximately 4 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;  . UC = ulcerative colitis; NHL = non-Hodgkin lymphoma; PCI = percutaneous coronary intervention

  • Gaming tackles back pain

    Built on a strong, simple strategy it used multiple channels to flood the world of men aged 18-40 with symptoms of Ankylosing Spondylitis (AS), a progressive, debilitating condition. ... With a barely pronounceable name, frequent confusion with common

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics